| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 8,829.81 | 7,219.68 | 6,677.08 | 5,300.26 |
yoy growth (%) | 22.3 | 8.12 | 25.97 | 16.53 |
Raw materials | -3,565.89 | -2,665.02 | -2,550.56 | -2,075.22 |
As % of sales | 40.38 | 36.91 | 38.19 | 39.15 |
Employee costs | -1,434.49 | -1,158.72 | -1,066.76 | -861.63 |
As % of sales | 16.24 | 16.04 | 15.97 | 16.25 |
Other costs | -2,019.07 | -1,447.01 | -1,592.11 | -1,370.76 |
As % of sales (Other Cost) | 22.86 | 20.04 | 23.84 | 25.86 |
Operating profit | 1,810.36 | 1,948.93 | 1,467.65 | 992.65 |
OPM | 20.5 | 26.99 | 21.98 | 18.72 |
Depreciation | -218.98 | -198.93 | -186.84 | -107.65 |
Interest expense | -37.9 | -42.93 | -38.71 | -32.37 |
Other income | 199.89 | 190.01 | 95.98 | 81.66 |
Profit before tax | 1,753.37 | 1,897.08 | 1,338.08 | 934.29 |
Taxes | -212.12 | -199.22 | -73.66 | -218.45 |
Tax rate | -12.09 | -10.5 | -5.5 | -23.38 |
Minorities and other | 0 | 0 | 0 | 0 |
Adj. profit | 1,541.25 | 1,697.86 | 1,264.42 | 715.84 |
Exceptional items | 0 | -12.78 | 0 | 0 |
Net profit | 1,541.25 | 1,685.08 | 1,264.42 | 715.84 |
yoy growth (%) | -8.53 | 33.26 | 76.63 | -18.94 |
NPM | 17.45 | 23.34 | 18.93 | 13.5 |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
